EBV infection is associated with development of the autoimmune disease systemic lupus erythematosus (SLE), and EBV can reactivate during SLE flares. Latent membrane protein 1 (LMP1) is an EBV-encoded oncogenic mimic of CD40 that can be re-expressed in PBMCs during SLE flares, as >90% of humans are latently EBV-infected. Whether LMP1 signaling exacerbates SLE is unknown. The phenotype of mice expressing a chimeric molecule with the mouse CD40 extracellular domain and the LMP1 intracellular signaling regions (mCD40-LMP1 transgenic [tg] ) includes enhanced autoreactivity, yet these mice do not develop fatal autoimmune disease. We hypothesized that LMP1-mediated activation signals cooperate with and/or amplify events that predispose individuals to development of autoimmunity. To determine which aspects of autoimmunity may be exacerbated by LMP1, we bred mCD40-LMP1tg mice to two lupus-prone strains, B6.Sle1 and B6.Sle3, and analyzed autoimmunity parameters. LMP1 + Sle1 +/+ mice developed enlarged lymphoid organs containing increased frequencies of germinal center, B cells, CD86 + B cells, and activated and memory T cells compared with non-tg littermates. Anti-histone Abs were elevated in serum of LMP1 + Sle1 +/+ mice, and they had signs of kidney pathology. LMP1 + Sle1 +/+ B cells produced increased IL-6 and upregulated CD86 to a higher degree following CD40 stimulation in vitro, suggesting that the in vivo autoimmune exacerbation is B cell intrinsic. In contrast, the LMP1 transgene has no additional effects on autoimmunity on the B6.Sle3 background. These data indicate that LMP1-induced effects can cooperate with distinct subsets of host genes that predispose to autoimmunity and can thus be an exacerbating factor in autoimmune disease via multiple mechanisms. The Journal of Immunology, 2010, 185: 4053-4062.
E pstein-Barr virus is a B lymphotropic g-herpesvirus that establishes a lifelong latent infection in .90% of humans (1, 2) . Despite the high seroprevalence of EBV in the normal human population, EBV infection is associated with increased incidence of childhood and adult systemic lupus erythematosus (SLE), in which EBV seroprevalence is .99% (3, 4) . Very few EBV-encoded proteins are expressed during latent infection of memory B cells. However, EBV can reactivate during conditions of profound immunosuppression and during flares of autoimmune diseases including rheumatoid arthritis and systemic lupus erythematosus (SLE) (5, 6) . Patients with SLE have increased EBV viral loads in PBMCs relative to healthy controls, suggesting that patients with SLE do not effectively control EBV latency (7) (8) (9) . EBV-encoded proteins, including latent membrane protein 1 (LMP1), are detected in PBMCs of patients with SLE only during flares of disease, suggesting that these proteins may contribute to disease pathogenesis or severity (10) .
LMP1 is a viral mimic of the TNFR family member CD40 and signals in an amplified and sustained manner relative to CD40 (11) . LMP1 possesses a six transmembrane-spanning domain that mediates ligand-independent activation and two cytoplasmic C-terminal activating regions that transduce intracellular signals by binding to TNFR-associated factors (12) . However, the ability of LMP1 to signal constitutively is not required for its amplified signaling to B cells, as signaling by domain-swapped molecules that replace the N-terminal and transmembrane domains with that of human or mouse (m)CD40 still deliver sustained and amplified signals to B cells (13, 14) . Signaling by mCD40-LMP1 or human CD40-LMP1 in B cells results in increased proinflammatory cytokine and Ig production, as well as CD80/86 upregulation compared with CD40 (14, 15) . Transgenic (tg) mice expressing a chimeric mCD40-LMP1 molecule under control of the mouse MHC class II Ea promoter and bred onto a CD40-deficient background, so the transgene is the only CD40 molecule expressed, were previously generated by our laboratory (15) . Previous work with this mouse demonstrates that the LMP1 cytoplasmic tail can substitute for CD40 signaling in many respects, restoring isotype switching, germinal center (GC) formation, and Ig affinity maturation in response to immunization with T-dependent Ags (15) . However, mCD40-LMP1tg mice on a CD40 2/2 background also have an unexpected autoimmune phenotype, consisting of spontaneous GC formation, increased frequency of splenic immature/activated B cells and plasmacytoid dendritic cells (DCs), elevated IL-6, IL-12, and TNF-a in serum, and elevated levels of anti-dsDNA and anti-phospholipid Abs (15, 16) . Additionally, these mice develop exacerbated disease in a mouse model of rheumatoid arthritis and collagen-induced arthritis (17) . Yet, mCD40-LMP1tg mice live a normal life span, suggesting that if LMP1 exacerbates autoimmunity, as suggested in human studies cited above, it must cooperate with the host genetic background to do so. However, the aspects of autoimmunity exacerbated by LMP1 expression and which sets of lupus-prone genes cooperate with LMP1 are unknown and are the focus of the current study.
Several spontaneous mouse models of SLE were previously created by various laboratories (18) . The NZM2410 strain develops fully penetrant, fatal glomerulonephritis by 6 mo of age (18) . To determine the individual genes responsible for this phenotype, congenic strains on the C57BL/6 background were created (19) . The B6.Sle1, B6.Sle2, and B6.Sle3 strains of mice bear a segment from chromosome 1, 4, or 7 of NZM2410, respectively, and display various aspects of the parental autoimmune pathology (18) (19) (20) . B6.Sle2 mice have a phenotype that is most consistent with that of the mCD40-LMP1tg mouse, displaying polyclonal B cell activation and elevated serum IgM (21) . B6.Sle1 mice do not display lymphosplenomegaly and rarely develop kidney disease with age (20) . Rather, this strain displays spontaneous T and B cell activation and produces high titers of anti-chromatin and anti-histone Abs (22, 23) . The T and B cell activation defects appear to be distinct and independent, as autoreactivity still occurs in B6.Sle1 mice with defects in T or B cell development (24) . B6.Sle3 mice have normal lymphoid organ size, but display spontaneous T and B cell activation in older (9-12-mo-old) mice, resulting from hyperactive DCs (25, 26) , and develop mild immune complexmediated kidney disease by 12 mo of age (20) . Genetic combination of these strains reveals that the B6.Sle1 locus is required for breaching tolerance to chromatin and that B6.Sle1Sle3 is the most potent dual loci combination, reconstituting most of the autoimmune phenotypes of the NZM2410 strain (27) (28) (29) .
LMP1 signals strongly activate B cells both in vitro and in vivo, resulting in increased secretion of proinflammatory cytokines including IL-6, upregulation of CD80/86, spontaneous GC formation, autoantibody production, and enlarged lymphoid organs, as discussed above. Thus, we hypothesized that the presence of these LMP1-mediated events would exacerbate disease in autoimmuneprone strains of mice by enhancing and/or cooperating with genetic factors predisposing to immune hyperactivation (13, 15, 30) . To test this hypothesis and determine which aspects of autoimmunity may be exacerbated by LMP1, we bred mCD40-LMP1tg (LMP1 + ) mice to B6.Sle1 and B6.Sle3 mice, as the B6.Sle2 phenotype appears redundant with the effects of LMP1. We characterized the phenotype of mice generated by these crosses, which include LMP1 + Sle1 +/+ , LMP1 + Sle3 +/+ , and non-tg littermates (LMs). All mice analyzed are homozygous for endogenous CD40. In this study, we observe that LMP1 cooperated with genes in the B6.Sle1, but not the B6.Sle3 strain. As the effects of the Sle3 genes are primarily on DCs, this suggests that LMP1 exerts its influence on autoimmunity mainly via the mechanism of B lymphocyte dysregulation. LMP1-Sle1 cooperation resulted in increased lymphoid organ size and evidence of kidney pathology characteristic of autoimmune disease. Multiple mechanisms likely contribute to this outcome, including demonstrated increased frequency of activated T and B cells, spontaneous GCs, and elevated levels of autoantibodies. Additionally, LMP1 + Sle1 +/+ B cells produced increased IL-6 and upregulated CD86 to a higher degree following CD40 stimulation in vitro, further supporting a B cell-intrinsic mechanism for the in vivo autoimmune exacerbation. We conclude that LMP1 induces gene activation that is nonredundant with the Sle1 phenotype and instead cooperates with the products of autoimmunitypredisposing genes affecting B and T cell activation to exacerbate autoimmunity. LMs. All mice were homozygous for endogenous CD40. Mice were age-and sex-matched and analyzed at 4-6 mo, 9 mo, or 12 mo of age. Mice were housed in a specific pathogen-free barrier facility with restricted access, and all procedures were performed as approved by the University of Iowa Animal Care and Use Committee (Iowa City, IA).
Materials and Methods

Abs and reagents
The following Abs were used for flow cytometry: FITC anti-peanut lectin (agglutinin) (PNA), unconjugated anti-CD16, FITC-, or PE-conjugated anti-CD3, anti-B220, anti-CD86, anti-CD40, anti-CD154, anti-CD23, anti-CD21/35, anti-IgM, anti-IgD, anti-CD44, anti-CD62L, anti-CD4, anti-CD8, anti-MHC class II, and allophycocyanin-conjugated anti-CD25 (eBioscience, San Diego, CA); PerCP-conjugated anti-B220, anti-CD4, and anti-CD8 and isotype control Ab (BD Biosciences, San Jose, CA).
The following Abs were used for cell stimulation: goat anti-mouse IgM F(ab9) 2 m-chain specific (anti-IgM; Jackson ImmunoResearch Laboratories, West Grove, PA) and hamster anti-mCD40 (HM40.3; eBioscience). AntiThy1.2 (HO13.4) mAb was purified by 50% saturated ammonium sulfate precipitation from serum-free cultures.
Hi5 insect cells infected with wild-type baculovirus (Hi5-WTBV) or a baculovirus encoding mCD154 (Hi5-mCD154) have been described previously (31) . Hi5 cells normally grow at room temperature, lyse at 37˚C, and do not overgrow cell cultures while providing a membrane-bound trimeric form of mCD154.
Cell isolation
T-depleted splenocytes (TDSs) used in the CD86 upregulation and IL-6 production experiments were prepared by treatment with anti-Thy1.2 (HO13.4) mAb and complement (Pel-Freez, Brown Deer, WI) as described (15) .
Flow cytometry
Single-cell suspensions were made from spleen and lymph node (LN) by dissociating tissue between two frosted-glass microscope slides. Erythrocytes were lysed using hypotonic ACK buffer. Cells were washed several times in ice-cold media. A total of 1 3 10 6 cells were stained with directly conjugated fluorescent Abs as described (15, 32) , washed, and fixed using BD Cytofix/Cytoperm (BD Biosciences) according to the manufacturer's instructions. Data were collected on an FACSCalibur (Becton Dickinson, Mountain View, CA) using CellQuest software (CellQuest, Tampa, FL). The results were analyzed using FlowJo software (Tree Star, San Carlos, CA), gating first on live cells.
In vitro CD86 upregulation and IL-6 production T-depleted splenocytes were stimulated in triplicate at 1 3 10 6 cells/well in a 24-well plate for 48 h with the following stimuli: medium only, goat antimouse IgM F(ab9) 2 m-chain-specific (anti-IgM) or hamster anti-mCD40 (HM40.3) Abs at 2 mg/ml, Hi5-WTBV or Hi5-mCD154 cells at 1 Hi5:10 B cells. Supernatants were analyzed for IL-6 by ELISA as described (31) . Cells were collected and stained with FITC-CD86 or FITC-Rat IgG1 as an isotype control Ab and analyzed by flow cytometry.
Serum autoantibody and IL-6 detection
Serum anti-dsDNA IgG and anti-dsDNA/histone IgG Ab titers were measured by ELISA as described (23); n = 9-11 female mice per genotype at 4-6 or 12 mo of age. IL-6 was detected using a commercial kit (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.
Kidney histology
Ten kidneys from 4-6-mo-old or 12-mo-old female LMP +
Sle1
+/+ and nontg LMs (1 kidney/mouse) were fixed in 10% neutral formalin, then processed and embedded in paraffin. Four-to five-micrometer sections were prepared with a microtome (HM 355, Microm, Walldorf, Germany) then stained with H&E with an automated slide stainer (Sakura DRS 601 Diversified Stainer, Sakura, Hayward, CA). Stained slides were mounted with Solvent 100 mounting media, and bright-field micrographs of stained sections were taken with a microscope (Olympus BX-51, Olympus, Melville, NY) fitted with an Olympus DP70 camera (Olympus). Slides were examined by a pathologist who was blinded to the study groups. Morphometric as-sessment was made on five random glomeruli per kidney selected for large size to best represent a mid-cross section of the glomerulus and those with distinct separation of the glomerulus from Bowman's capsule for accuracy.
Results
Lymphoid organ size in LMP1
+ Sle1 +/+ mice +/+ mice was due to cooperation between LMP1 and genes in the Sle1 interval. The increased LN weight was accompanied by an increase in total cell number, which included a statistically significant increase in the number of B and T cells recovered from LMP1 + Sle1 +/+ LN (Tables  I, II) . However, there was no effect of the LMP1 transgene on lymphoid organ size or cell number on the B6.Sle3 background. Thus, LMP1 did not cooperate with genes in the Sle3 interval to enhance autoimmunity. The lack of significantly increased LN and spleen weight in LMP1 + versus LMP1 2 BL/6 mice in this study could be due to the presence of endogenous CD40, which can ameliorate some of the effects of LMP1 in vivo (L. L. Stunz, unpublished observations).
Spontaneous GC formation in LMP1
Given the enlarged lymphoid organs observed in LMP1 + Sle1
+/+ mice, we further evaluated the spleen and LN to determine whether spontaneous lymphocyte activation was the mechanism of this enlargement. The frequencies of B cells, CD4 + T, CD8 + T, and myeloid cells were normal in all mouse strains, regardless of the presence of the LMP1 transgene. The splenic marginal zone, follicular, and immature B cell compartments, identified by the expression of CD23 and CD21/35, were also examined. The frequency of splenic marginal zone and follicular B cell populations was not significantly different among the mouse strains (Supplemental Fig.   1 ). The CD23 lo CD21/35 lo B220 + population (population L) (15, 16) was occasionally increased in some B6.Sle1 and B6.Sle3 mice relative to LMP1-BL/6 mice (Supplemental Fig. 1 ). However, no additional increase in the frequency of this population was observed in LMP1 + Sle1 +/+ or LMP1 + Sle3 +/+ mice (Supplemental Fig. 1 ). GCs are specialized lymphoid structures within the splenic white pulp that only form postimmunization. In the GC, B cells receive survival signals, undergo Ig isotype switching and affinity maturation, and differentiate into Ab-secreting plasma cells and memory B cells (33) . Spontaneous GC formation occurs in several mouse models of SLE (18, 33, 34 ). An increase in spontaneous GCs could provide a mechanism for increased production of autoantibodies. To test whether GC B cells were forming in the enlarged spleens of LMP1 + Sle1 +/+ mice, the presence of spontaneous GC in LMP1 + Sle1 +/+ mice was examined and seen by immunofluorescence staining of frozen splenic sections (data not shown). However, quantification of splenic GCs by this method is technically difficult. Thus, we analyzed LMP1 + Sle1
+/+ mice for the presence of spontaneous splenic GC B cells by flow cytometry using a reliable, accepted quantitative method (35) . Single-cell splenocyte suspensions were gated on live cells and examined for expression of B220 and PNA, a lectin that binds sugar residues highly expressed on GC B cells (15) . As shown in Fig.  2A , significantly increased frequencies of GC B cells were consistently identified in female LMP1 + Sle1 +/+ mice, but only rarely in LM or LMP1 + Sle3 +/+ mice, even at 12 mo of age (Fig. 2B ). These data demonstrate that LMP1 and Sle1, but not Sle3 gene products cooperate to enhance the formation of GC B cells in unimmunized mice, an indicator of, and contributor to the mechanism of autoimmunity.
CD4
+ and CD8 + T cell activation in lymphoid organs of LMP1 + Sle1 +/+ mice GC formation is typically a T cell-dependent event (36) , and LMP1 + Sle1 +/+ mice displayed evidence of spontaneous GC formation. Additionally, as discussed earlier, the Sle1 gene cluster predominantly affects activation of T and B lymphocytes as compared with the principal effects of Sle3 genes on myeloid cells. Thus, we investigated whether T cells were also spontaneously activated in LMP1 + Sle1 +/+ mice. Although the frequencies of CD4 + and CD8 + T cells were normal in LMP1 + Sle1 +/+ mice compared with control strains, we observed increases in the total num- bers of these cell types in LNs (Tables I, II (Table I) . LMP1 + Sle3 +/+ mice had no additional changes in naive or activated T cell frequency or cell number at 4-6 mo of age. No differences in memory CD8 + T cell frequency were observed in spleen or LNs at 4-6 mo of age in any of the mouse strains (Table III) . The increased frequency and total number of activated/memory T cells in lymphoid organs of LMP1 +
Sle1
+/+ mice was even more pronounced in 12-mo-old mice (Tables  II, IV) . These mice had very few naive CD4 + and CD8 + T cells in (Tables II, IV) (Tables II,  IV) . These data highlight another mechanism by which LMP1 cooperates with genes in the Sle1 interval to enhance CD4 and CD8 
Sle3
+/+ mice in the 12-mo age group had significantly higher levels of GCBC (5-8%) than their age-matched controls (1-2%), and were counted as positive. The numbers above each column represent the number of mice of each genotype with elevated percentage of GCBC out of all mice analyzed. The p values were determined by x 2 test. GCBC, GC B cells. T cell activation and memory cell formation, which in turn can enhance B cell activation and autoantibody production. , and LMs were stimulated for 48 h via CD40 or the BCR and analyzed for CD86 expression. Unstimulated TDSs from all mouse strains expressed very low levels of CD86 (Fig. 3, gray dashed and black solid lines) , and all upregulated CD86 to the same degree following BCR stimulation (Fig. 3 , left upper and lower panels, gray solid and black dashed lines). However, stimulation via CD40 induced a higher degree of CD86 expression on LMP1 
Sle1
+/+ mice B6.Sle1 mice produce high titers of Abs reactive against nuclear Ags, particularly chromatin and histones (20, 23) , and LMP1 signaling in mice enhances serum anti-dsDNA Abs, as discussed above. Thus, enhanced spontaneous T and B cell activation in LMP1 + Sle1 +/+ mice led us to evaluate serum of female mice at 4-6 mo or 12 mo of age for the presence and levels of anti-dsDNA and anti-histone/dsDNA IgG (23) . Levels of total IgM, IgA, IgG1, IgG2b, and IgG3 were measured by ELISA and were not significantly different between B6.Sle1 and B6.Sle3 mice or their LMP1 + LMs (data not shown). As shown in Fig. 4 , LMP1 + Sle1
+/+ female mice had significantly higher serum levels of anti-dsDNA and anti-histone/dsDNA IgG at 6 mo of age than LMP1 2 Sle1
+/+ mice. At 12 mo of age, the difference was no longer detectable in serum. In contrast, even very low titers of anti-dsDNA and antihistone/dsDNA IgG were not detected in serum of LMP1 + Sle3 +/+ mice or their non-tg LMs, even at 12 mo of age (Fig. 4) . These data, together with those in Figs. 2 and 3 , indicate that not only are B cells more highly activated in LMP1 + Sle1 +/+ mice compared with the non-tg LMs, but this increased B cell activation leads to production of autoantibodies that may contribute to kidney pathology.
IL-6 production by LMP1
+ Sle1 +/+ B cells IL-6 is a proinflammatory cytokine that contributes to Ab production and is pathogenic in autoimmune responses (37) . IL-6 is elevated in serum of mCD40-LMP1tg mice, as well as in serum of B6.Sle1 mice (15, 38) . Elevated IL-6 production by B6.Sle1 myeloid cells inhibits suppression of T cell activation by T regulatory cells (39) . The enhanced autoimmunity observed in LMP1 + Sle1
+/+ mice, as measured by multiple parameters, was also reflected by IL-6 production. Serum IL-6 levels in 4-6-mo-old LMP1 + Sle1
+/+ mice were not increased by statistically significant amounts over LMP1 2 Sle1 +/+ levels (Fig. 5A ). Twelve-month-old LMP1 + Sle1
+/+ mice, however, did show a trend toward elevated serum IL-6, which correlated with autoantibody production. There was no effect of the LMP1 transgene on serum IL-6 levels in B6.Sle3 mice, even in 12-mo-old animals (Fig. 5A ). Serum levels of other proinflammatory cytokines including IFN-g, IL-12, and IL-17 were analyzed with no significant differences observed between LMP1 + Sle1 +/+ , LMP1 + Sle3 +/+ , and the respective non-tg LMs (data not shown). To test whether LMP1 signaling was the mechanism responsible for enhanced IL-6 production by LMP1-expressing B6.Sle1 B cells, TDSs from LMP1 + BL/6, LMP1 + Sle1 +/+ , LMP1 + Sle3 +/+ , and LMs were stimulated for 24 h with insect cells expressing mCD154, the ligand for mCD40, and for the tg mCD40-LMP1 or anti-IgM Ab as a control. CD154 stimulation was used to measure this parameter because, unlike most CD40-mediated B cell effects, IL-6 production requires the membrane-bound ligand for CD40, and agonistic Ab cannot act as a substitute (31) . CD40 expression on B cells from LMP1 + BL/6, LMP1 + Sle1 +/+ , and LMP1 + Sle3 +/+ mice was equivalent, although slightly elevated relative to LMs (data not shown). B6.Sle1 and B6.Sle3 TDSs produced increased amounts of IL-6 relative to BL/6 controls, consistent with previously published results (26, 38, 39) . There was no effect of the LMP1 transgene on IL-6 production by either BL/6 or B6.Sle3 TDSs. However, LMP1 + Sle1 +/+ TDSs produced ∼2-fold more IL-6 following CD40 signaling relative to non-tg LMs (Fig. 5B) , consistent with the concept that LMP1 signals to B cells effectively cooperate with genes in the B6.Sle1 interval. Levels of other proinflammatory cytokines including TNF-a, IFN-g, IL-12, and IL-17 were analyzed within these same culture supernatants with no significant differences observed between LMP1 + Sle1 +/+ , LMP1 + Sle3 +/+ , and the respective non-tg LMs (data not shown).
Kidney pathology in LMP1 +
Sle1
+/+ mice Whereas B6.Sle1 mice have high levels of anti-histone and antichromatin Ab, neither proteinuria nor immune complex deposition is noted even in kidneys of aged mice, and ,20% of B6.Sle1 mice display evidence of mild glomerulonephritis (20) . LMP1 signals clearly enhance various events contributing to autoimmune disease in B6.Sle1 mice, so we next examined LMP1 + Sle1 +/+ female mice for evidence of enhanced nephritis compared with non-tg LMs at 4-6 mo and 12 mo of age. Although consistent differences in proteinuria were not observed (not shown), histopathologic examination showed differences between the LMP1 + SLE1
+/+ and non-tg LM groups at both time points. Kidneys from 4-6-mo-old and 12-mo-old LMP1 + SLE1 +/+ groups had glomeruli with noticeably increased cellularity (Fig. 6A) confirmed by mor- +/+ (right panels), and non-tg LMs, 9-11 mice/group, was analyzed for the presence of anti-dsDNA IgG (top panels) and anti-dsDNA/histone IgG (bottom panels) by ELISA. Serum from C57BL/6 mice (n = 2) was included as a nonautoimmune negative control, whereas serum from autoimmune BXSB and MRL/lpr mice was a positive control for the assay. pp , 0.005; ppp , 0.0005 as determined by two-tailed Student t test. +/+ groups included mild to moderate interstitial lymphoplasmacytic infiltrates (Fig. 6A, arrows) , glomerular hypertrophy, periglomerular fibrosis, and increased eosinophilic mesangial matrix.
Discussion
More than 90% of humans are latently infected with EBV, but this does not in itself lead to autoimmune disease. However, transient re-expression of LMP1 has been associated with flares of human SLE and may exacerbate the disease, particularly in genetically predisposed individuals (10) . Thus, to examine the potential ability of LMP1 signaling to cooperate with the products of other autoimmune disease-related gene clusters in exacerbating autoimmunity, we studied its effects in two strains of SLE-prone mice, B6.Sle1 and B6.Sle3, which express specific subsets of autoimmunity-predisposing genes. LMP1 + Sle1 +/+ mice displayed evidence of enhanced autoreactivity, including increased lymphoid organ size and kidney pathology. Mechanisms contributing to this enhanced autoimmunity include number and frequency of activated T and B cells, spontaneous GC formation, anti-histone Ab production, and enhanced IL-6 production and CD86 upregulation following LMP1 signaling to B cells. We did not detect any significant differences in cytokine production by CD4 + T cells following stimulation with anti-CD3 and anti-CD28 Abs in vitro, including IL-2, IL-4, IL-6, IL-17, or IFN-g by LMP1 +/+ (data not shown). These data support the conclusion that the effect of LMP1 on autoimmunity is primarily B cell intrinsic, with LMP1-activated Sle1 +/+ B cells upregulating CD86 to a higher degree than their non-tg counterparts, which in turn drives increased activation of CD4 + T cells in vivo. These activated T cells can then further amplify dysregulated B cell activation, enhancing GC formation and autoantibody production. In sharp contrast to the B6.Sle1 strain, there was no effect of LMP1 signaling on autoimmunity in vitro or in vivo in the B6.Sle3 strain. Thus, LMP1 cooperated with the products of genes in the B6.Sle1, but not Sle3 interval to enhance autoimmunity.
Many genes of immunologic interest reside within the B6.Sle3 locus, including CD22, tristetraprolin, TGF-b, and Bcl3 (20, 25) . However, to date, no allelic differences between C57BL/6 and NZM2410 have been found. Thus, the genes responsible for the B6. Sle3 autoimmune phenotype have yet to be identified. Our studies show that LMP1 signaling does not cooperate with Sle3 interval gene products in vivo or in vitro. One interpretation of our results is that LMP1 cannot signal at all in the B6.Sle3 background due to mutations in required yet unidentified genes. However, in vitro activation of mitogen-and stress-activated protein kinases by LMP1 signaling was similar between LMP1 + Sle1 +/+ and LMP1 + Sle3 +/+ B cells (data not shown), suggesting that early events in LMP1 signaling to B cells are intact in both strains. An alternative explanation is that the Sle3 gene products mainly alter the function of DCs, and LMP1 signals predominantly alter B cells and their interactions with T cells.
Several candidate genes within the B6.Sle1 interval that predispose to autoimmunity have been identified and include polymorphisms in complement receptor 2 (CR2) as well as the signaling lymphocyte activation molecule and signaling lymphocyte activation molecule-associated protein family member Ly108 (40, 41) . The NZM2410 alleles are thought to contribute to decreased strength of BCR signaling during B cell development in the bone marrow, allowing autoreactive cells to escape apoptosis and populate peripheral lymphoid tissues (40, 41) . Ly108 in particular is expressed on both B and T cells, where it plays a role in cell adhesion and costimulation of TCR signaling (41) (42) (43) . Although expression of Ly108 was increased in B6.Sle1 B cells ex vivo, there was no additional detectable increase of Ly108 expression on LMP1 + Sle1 +/+ B cells (data not shown). Furthermore, stimulation with CD40 agonists (which will signal through both endogenous CD40 and the chimeric mCD40-LMP1 protein) in vitro did not further increase Ly108 expression in LMP1 + Sle1 +/+ versus LMP1
2
Sle1
+/+ B cells (data not shown). Based on these results, we conclude that LMP1 signaling did not enhance activation either in vitro or in vivo by affecting Ly108 expression in B6.Sle1 B cells.
Therefore, LMP1 and B6.Sle1 genes may be acting in distinct yet cooperative pathways as proposed in the following model (Fig. 7) . Ly108 and CR2 are thought to function during B cell development in the bone marrow, where these receptors fine-tune BCR signaling (40, 41) . During B cell selection, a strong BCR signal is indicative of an autoreactive cell and leads to apoptosis. The NZM2410 alleles of Ly108 and CR2 lead to weaker signals through the BCR, which may allow autoreactive B cells to escape deletion and populate peripheral lymphoid tissues (40, 41) . Once in the periphery, signaling by LMP1, for which re-expression from latency may be transiently triggered by inflammation, enhances upregulation of CD86, which further costimulates T cells. LMP1 signaling in the B6.Sle1 background also leads to enhanced B cell activation, which aids in plasma cell formation and contributes to autoimmunity (15) . LMP1 cooperates with Sle1 interval genes in a quantitative manner as outlined above, including the production of anti-dsDNA/histone and anti-dsDNA IgG, yet is unable to induce kidney disease, resulting in consistent, severe proteinuria (data not shown). These events may require other SLE genes (i.e., Sle3) or EBV-encoded genes expressed during viral reactivation (i.e., LMP2A, BZLF1) (10) .
This study demonstrates that the EBV-encoded CD40 mimic LMP1 can exacerbate autoimmunity in vivo by cooperating with the products of specific subsets of predisposing genes, for which specific identification is an important future goal. Our results suggest that LMP1 expression during an SLE flare exacerbates autoimmunity via multiple mechanisms, including direct effects on B cell activation, enhancement of B cell costimulatory properties, and resultant enhanced T cell activation, which can in turn further activate B cells. Because SLE susceptibility genes within the B6. Sle1 interval have also been identified in humans, inhibiting LMP1 signaling during disease flares may serve as a potent therapeutic target for SLE treatment.
